1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Idiopathic Pulmonary Fibrosis: KOL Insight

Idiopathic Pulmonary Fibrosis: KOL Insight

  • May 2015
  • -
  • Firstword Pharma

Roche’s Esbriet, (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) are the only approved therapies for Idiopathic Pulmonary Fibrosis (IPF). Will either be able to establish themselves as first choice, and what future developments could unlock the market?

Idiopathic Pulmonary Fibrosis: KOL Insight critically examines this therapeutic area through the expert insights of 12 leading US and European Key Opinion Leaders. This comprehensive report presents business-critical analysis for the pharma and drug discovery community and reveals what influences prescribing decisions and how clinicians see pipeline products changing the future treatment paradigm for IPF.

Is combination therapy the way of the future for Idiopathic Pulmonary Fibrosis?

Gain KOL insights on key topics such as the combination therapies that could work, the clinical trials that are needed, as well as how drug development and diagnostic players could grow or enter this market sector that has high levels of clinical unmet need.

Gain Answers to Critical Questions

How can Roche leverage growing evidence of Esbriet’s mortality benefit for wider prescribing?

What competitive advantage does the once-daily dosing regimen of Boehringer Ingelheim’s Ofev provide?

What are the key patient characteristics that determine a clinician’s decision to prescribe Esbriet or Ofev, and what lessons are there for Roche, Boehringer Ingelheim and companies developing new pipeline therapies?

Esbriet and Ofev in combination – is it likely, desirable, or are the risks to patient safety too high?

How might the development of biomarkers change prescribing choices, and what challenges do developers face?

Pricing is a contentious issue limiting, in some cases, patient access – what can be done?

KOLs are cautiously enthusiastic about the prospects of Fibrogen’s FG-3019, Gilead’s simtuzumab and Biogen STX-100 – why, and what insights could influence these company’s research efforts?

Key Benefits

Know the clinical opinions of KOLs and formulate effective strategies for product positioning, clinician communication and patient support
Review KOL attitudes to important clinical trials such as ASCEND, INPULSIS 1&2, TOMORROW, RAINIER, ATLAS
Map treatment options to IPF patient sub-groups and know why and when a particular therapy is chosen
Identify product and patient characteristics that the KOLs think are the most important in terms of prescribing decisions
Discover which novel pipeline products and combination trials KOLs believe could have a significant impact, and understand the implications for clinical trial design
Understand why KOLs see combination therapy as the way to progress

KOL Views on Therapies
Pipeline Therapies:
Biogen, STX-100
Bristol-Myers Squibb, BMS-986020
FibroGen, FG-3019
Gilead, simtuzumab
MedImmune/AstraZeneca, tralokinumab
Roche, lebrikizumab
Marketed Therapies:
Boehringer Ingelheim, Ofev (nintedanib)
Roche, Esbriet (pirfenidone)

Key Opinion Leaders

North America

Dr Harold Collard, University of California San Francisco, California
Dr Joseph A Lasky, Tulane University, Louisiana
Dr David Lederer, Columbia University, New York
Professor Steven D Nathan, Inova Fairfax Hospital, Virginia
Professor Jesse Roman, University of Louisville , Kentucky
Professor Victor J Thannickal, University of Alabama at Birmingham, Alabama


Professor Bruno Crestani, Hopital Bichat Paris, France
Professor Roland M du Bois, Imperial College London, UK
Dr Maria Molina-Molina, Bellvitge University Hospital, Spain
Anonymous KOL, Germany
Anonymous KOL, Germany
Anonymous KOL, Germany

Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, May 2015.
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Table Of Contents

Idiopathic Pulmonary Fibrosis: KOL Insight
1.Executive Summary
2.Research Objectives
3.Research Focus
4.Current Treatments

6.Marketed Drugs
7.Esbriet (pirfenidone; Roche)
8.Ofev (nintedanib; Takeda)
9.Pipeline Drugs

11.FG-3019 (FibroGen)
12.simtuzumab (Gil

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  


View report >

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  



  • South Korea  

View report >

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.